[Results of animal experiments and clinical testing with Noleptan].
D000813:Anilides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D000818:Animals; D000996:Antitussive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001775:Blood Circulation / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D006801:Humans; D008170:Lung Compliance / Q000187:drug effects; D008744:Methylamines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D051379:Mice; D009025:Morpholines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D012131:Respiratory Insufficiency / Q000188:drug therapy; D014692:Ventilation-Perfusion Ratio / Q000187:drug effects
D000813:Anilides; D000996:Antitussive Agents; D008744:Methylamines; D009025:Morpholines
Ergebnisse der tierexperimentellen und klinischen Prüfung mit Noleptan.